ABEV vs. BF.B: Which Stock Might Be the Better Value?

Investors looking into the alcoholic‑beverage space often compare Ambev (ABEV) and Brown‑Forman Corporation (BF.B) — but which is the better value pick right now? While a full version of the original article was blocked, recent publicly available analysis suggests some key takeaways. On the one hand, Brown‑Forman appears to be under pressure: its upcoming Q2 fiscal 2026 results are expected to show a year‑over‑year earnings decline, with revenues possibly down about 6% compared with the prior year. Earnings‑per‑share are forecast at roughly $0.48, about 12.7% lower than the same quarter last year. Its “Earnings ESP” indicator is negative (–4.84%), making a surprise upside less likely, even though its current rating sits at Zacks Rank #2 (Buy). On the other hand, Ambev — while not a new name for value investors — has often been highlighted for its relatively attractive valuation among alcohol‑sector peers. For example, in prior comparisons with other companies, Ambev has come out ahead due to modest forward P/E, reasonable price-to-book, and healthier earnings outlook under the same zoning system. Bottom line: while Brown‑Forman carries global brand strength and premium‑spirits exposure, its near‑term earnings softness and valuation premium may give some investors pause. Ambev, in contrast, stands out as a potentially more value‑oriented option — especially for those inclined toward conservative valuations in the beverage sector. && #stockmarket #investing #ABEV #BFB && #stockmarket #investing #ABEV #BFB #SlimScan #GrowthStocks #CANSLIM